New and Noteworthy

Showing 9 of 0 results

• Flatiron Health Announces Upcoming Research Presentations at the San Antonio Breast Cancer Symposium 2024
  • Press releases
  • Breast cancer
• Comparative overall survival of CDK4/6is plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting

  San Antonio Breast Cancer Symposium

  • Publication summary
  • Publications
  • Metastatic breast cancer
  • Breast cancer
• Tolerability of first-line treatment with ribociclib for metastatic breast cancer using two large US data sources

  San Antonio Breast Cancer Symposium

  • Publication summary
  • Publications
  • Metastatic breast cancer
  • Breast cancer
• Clinical characteristics and treatment persistence in US patients with HR+/HER2-, node positive early breast cancer treated with abemaciclib: Real-world study from first year after approval

  San Antonio Breast Cancer Symposium

  • Publication summary
  • Publications
  • Breast cancer
• Real-world demographics, clinical characteristics, and treatment patterns among US patients with HER2-negative early breast cancer and germline BRCA mutations since 2021

  San Antonio Breast Cancer Symposium

  • Publication summary
  • Publications
  • Breast cancer
• Case study: Early-onset cancer trends in Japan and the US
  • Case study
  • Gastric/Esophageal cancer
  • Colorectal cancer
• ASH 2023 Preview Webinar: Innovative approaches to evidence generation that unlock key insights in hematologic cancer
  • Real-world evidence
  • Video
  • Health equity
  • Webinar
• Willowglade Technologies and Flatiron Health partner to enhance patient engagement and practice operations
  • Point of care
  • Press releases
• Flatiron Health announces research to be presented at American Society of Hematology Annual Meeting and Exposition
  • Real-world evidence
  • Press releases